К проблеме безопасности вакцинопрофилактики COVID-19 у ревматологических пациентов: итоги и перспективы

   Пандемия коронавирусной болезни 2019 (novel coronavirus disease, COVID-19) привлекла внимание медицинского сообщества к новым клиническим и фундаментальным проблемам иммунопатологии заболеваний человека. Несмотря на снятие режима международной чрезвычайной ситуации и объявление о завершении пандемии COVID-19, Всемирная организация здравоохранения подчеркнула необходимость дальнейшей поддержки научных исследований по совершенствованию вакцин, способствующих снижению интенсивности распространения вируса и имеющих перспективы широкого применения. В настоящем обзоре представлены результаты исследований последних лет по проблеме безопасности вакцинации против COVID-19 у больных ревматическими заболеваниями (РЗ). В целом частота обострения РЗ после вакцинации против COVID-19 представляется достаточно низкой (5–10 %) и не имеет статистически значимых ассоциаций с конкретной вакциной или проводимой противоревматической терапией. Обозначены перспективы применения моноклональных антител с целью доконтактной профилактики COVID-19 у больных РЗ.

1. From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19 pandemic. https://www.who.int/publications/i/item/WHO-WHE-SPP-2023.1.

2. Куликов А. Н., Муравьева Н. В., Белов Б. С. Гриднева Г. И., Аронова Е. С., Верижникова Ж. Г. и др. Эффективность, иммуногенность и безопасность комбинированной векторной вакцины Гам-КОВИД-Вак у больных ревматическими заболеваниями. Антибиотики и химиотер. 2024; 69 (7–8): 44–52. doi: 10.37489/0235-2990-2024-69-7-8-44-52.

3. Polack F. P., Thomas S. J., Kitchin N., Absalon J., Gurtman A., Lockhart S. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383 (27): 2603–2615. doi: 10.1056/NEJMoa2034577.

4. Connolly C. M., Ruddy J. A., Boyarsky B. J., Barbur I., Werbel W. A., Geetha D. et al. Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol. 2022 Jan; 74 (1): 28–32. doi: 10.1002/art.41924.

5. Furer V., Eviatar T., Zisman D., Peleg H., Paran D., Levartovsky D. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80 (10): 1330–1338. doi: 10.1136/annrheumdis-2021-220647.

6. Fragoulis G. E., Bournia V. K., Mavrea E., Evangelatos G., Fragiadaki K., Karamanakos A. et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatol Int. 2021 Nov 5: 1–9. doi: 10.1007/s00296-021-05039-3.

7. Barbhaiya M., Levine J. M., Bykerk V. P., Jannat-Khah D., Mandl L. A. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis. 2021; 80 (10): 1352–1354. doi: 10.1136/annrheumdis-2021-220732

8. Geisen U. M., Berner D. K., Tran F., Sümbül M., Vullriede L., Ciripoi M., et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021; 80 (10): 1306–1311. doi: 10.1136/annrheumdis-2021-220272

9. Ramirez G. A., Della-Torre E., Moroni L., Yacoub M. R., Dagna L.; OSR-COVAX study group. Correspondence on «Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort». Ann Rheum Dis. 2021; 80 (10): e159. doi: 10.1136/annrheumdis-2021-220539.

10. Cherian S., Paul A., Ahmed S., Alias B., Manoj M., Santhosh A. K. et al. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int. 2021; 41 (8): 1441–1445. doi: 10.1007/s00296-021-04917-0.

11. Medeiros-Ribeiro A. C., Aikawa N. E., Saad C. G. S., Yuki E. F. N., Pedrosa T., Fusco S. R. G. et al. Immunogenicity and safety of the CoronaVac in-activated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021; 27 (10): 1744–1751. doi: 10.1038/s41591-021-01469-5.

12. Fan Y., Geng Y., Wang Y., Deng X., Li G., Zhao J. et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large realworld survey on inactivated COVID-19 vaccines. Ann Rheum Dis. 2022; 81 (3): 443–445. doi: 10.1136/annrheumdis-2021-221736.

13. Pinte L., Negoi F., Ionescu G. D., Caraiola S., Balaban D. V., Badea C. et al. COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases. J Pers Med. 2021; 11 (12): 1283. doi: 10.3390/jpm11121283.

14. Braun-Moscovici Y., Kaplan M., Braun M., Markovits D., Giryes S., Toledano K. et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–1321. doi: 10.1136/annrheumdis-2021-220503.

15. Rotondo C., Cantatore F. P., Fornaro M., Colia R., Busto G., Rella V. et al. Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study. Vaccines (Basel). 2021; 9 (7): 730. doi: 10.3390/vaccines9070730.

16. Esquivel-Valerio J. A., Skinner-Taylor C. M., Moreno-Arquieta I. A., Cardenas-de la Garza J. A., Garcia-Arellano G., Gonzalez-Garcia P. L. et al. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int. 2021; 41 (12): 2105–2108. doi: 10.1007/s00296-021-05017-9.

17. Sattui S. E., Liew J. W., Kennedy K., Sirotich E., Putman M., Moni T. T., et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey. RMD Open. 2021; 7 (3): e001814. doi: 10.1136/rmdopen-2021-001814.

18. Boekel L., Kummer L. Y., van Dam K. P. J., Hooijberg F., van Kempen Z., Vogelzang E. H. et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021; 3 (8): e542–e545. doi: 10.1016/S2665-9913(21)00181-8.

19. Bartels L. E., Ammitzbøll C., Andersen J. B., Vils S. R., Mistegaard C. E., Johannsen A. D. et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2021; 41 (11): 1925–1931. doi: 10.1007/s00296-021-04972-7.

20. Felten R., Kawka L., Dubois M., Ugarte-Gil M. F., Fuentes-Silva Y., Piga M., Arnaud L. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021; 3 (9): e613–e615. doi: 10.1016/S2665-9913(21)00221-6.

21. Izmirly P. M., Kim M. Y., Samanovic M., Fernandez-Ruiz R., Ohana S., Deonaraine K. K. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2021: 10.1002/art.41937. doi: 10.1002/art.41937.

22. Zavala-Flores E., Salcedo-Matienzo J., Quiroz-Alva A., Berrocal-Kasay A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022; 41 (5): 1349–1357. doi: 10.1007/s10067-021-05980-5.

23. Sciascia S., Costanzo P., Radin M., Schreiber K., Pini M., Vaccarino A. et al. Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. Lancet Rheumatol. 2021; 3 (12): e832. doi: 10.1016/S2665-9913(21)00320-9.

24. Hasseli R., Hoyer B., Lorenz H., Pfeil A., Richter J., Regierer A. et al. Safety of COVID-19 vaccines after first vaccination in patients with rheumatic diseases in a patient reported survey. Arthritis Rheumatol. 2021; 73 (Suppl 10): Abstr.0100.

25. Michaud K., Cornish A., Freifeld A., Katz P., Wipfler K. COVID-19 mRNA vaccine side effects among individuals with rheumatic disease. Arthritis Rheumatol. 2021; 73 (Suppl 10): Abstr.0116.

26. Gomez-Puerta J., Sapena N., Sarmiento-Monroy J., Azuaga A., Ruiz-Esquide V., Frade-Sosa B. et al. The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases. Arthritis Rheumatol. 2021; 73 (Suppl 10): Abstr.0114.

27. Carbone A., Vukatana G., Vandelli E., Trevisani M., Rossi E., Mulè R., Fusconi M. Flares and side effects after COVID-19 vaccination in patients with rheumatic diseases. Arthritis Rheumatol. 2021; 73 (Suppl 10): Abstr.1550.

28. Буланов Н. М., Новиков П. И., Гуляев С. В., Смитиенко И. О., Мешков А. Д., Бородин О. О., и др. Переносимость вакцины Гам-КОВИД-Вак (Спутник V) у взрослых пациентов с иммуновоспалительными ревматическими заболеваниями. Клин фармакол тер. 2021; 30 (4): 23–28. doi: 10.32756/0869-5490-2021-4-23-28.

29. Machado P. M., Lawson-Tovey S., Strangfeld A., Mateus E. F., Hyrich K. L., Gossec L. et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022; 81 (5): 695–709. doi: 10.1136/annrheumdis-2021-221490.

30. Younis A. A., Ridha A. A., Humadi Y. A., Jassim N. A., Awadh N. I., Maroof A. et al. Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases. Mediterr J Rheumatol. 2024; 35 (1): 123–133. doi: 10.31138/mjr.140223.sof.

31. Liu S., Jin Z., Feng X., Da Z., Tang Y., Hu H. et al. Efficacy and safety of in-activated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study. Int J Rheum Dis. 2024; 27 (5): e15166. doi: 10.1111/1756-185X.15166.

32. Zhang X., Li Y, Dai C., Chu Y., Luan C., Wang G. Safety and efficacy of in-activated SARS-CoV-2 vaccine in patients with rheumatic diseases and serum antibody changes post-omicron variant infection. Rheumatol Ther. 2024; 11 (1): 191–200. doi: 10.1007/s40744-023-00630-5.

33. Cruz V. A., Guimarães C., Rêgo J., Machado K. L. L. L., Miyamoto S. T., Burian A. P. N. et al. Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer. Adv Rheumatol. 2024; 64 (1): 58. doi: 10.1186/s42358-024-00397-5.

34. Doskaliuk B., Ravichandran N., Sen P., Day J., Joshi M., Nune A. et al. Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study. Rheumatol Int. 2023; 43 (9): 1651–1664. doi: 10.1007/s00296-023-05345-y.

35. Ramirez G. A., Asperti C., Cucca V., Yacoub M. R. Challenges to vaccination against SARS-CoV-2 in patients with immune-mediated diseases. Vaccines (Basel). 2021; 9 (10): 1147. doi: 10.3390/vaccines9101147.

36. Khan N., Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021; 161 (3): 827–836. doi: 10.1053/j.gastro.2021.05.044.

37. Sequeira J. F., Cesic D., Keser G., Bukelica M., Karanagnostis S., Khamashta M. A., Hughes G. R. Allergic disorders in systemic lupus erythematosus. Lupus. 1993; 2 (3): 187–191. doi: 10.1177/096120339300200311.

38. Mahil S. K., Bechman K., Raharja A., Domingo-Vila C., Baudry D., Brown M. A. et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021; 3 (9): e627–e637. doi: 10.1016/S2665-9913(21)00212-5.

39. Simon D., Tascilar K., Fagni F., Krönke G., Kleyer A., Meder C. et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021; 80 (10): 1312–1316. doi: 10.1136/annrheumdis-2021-220461.

40. Engler R. J., Nelson M. R., Klote M. M., VanRaden M. J., Huang C. Y., Cox N. J. et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008; 168 (22): 2405–14. doi: 10.1001/archinternmed.2008.513.

41. Pons-Estel B. A., Catoggio L. J., Cardiel M. H., Soriano E. R., Gentiletti S., Villa A. R. et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among «Hispanics». Medicine (Baltimore). 2004; 83 (1): 1–17. doi: 10.1097/01.md.0000104742.42401.e2.

42. Hernández Cruz B., Alonso F., Calvo Alén J., Pego-Reigosa J. M., López-Longo F. J., Galindo-Izquierdo M. et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus. 2020; 29 (1): 27–36. doi: 10.1177/0961203319889667.

43. Assawasaksakul T., Sathitratanacheewin S., Vichaiwattana P., Wanlapakorn N., Poovorawan Y., Kittanamongkolchai W. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series. RMD Open. 2021; 7 (3): e002019. doi: 10.1136/rmdopen-2021-002019.

44. Allen-Philbey K., Stennett A., Begum T., Johnson A. C., Dobson R., Giovannoni G. et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord. 2021; 52: 103028. doi: 10.1016/j.msard.2021.103028.

45. Klugar M., Riad A., Mekhemar M., Conrad J., Buchbender M., Howaldt H. P., Attia S. Side Effects of mRNA-Based and viral vector-based COVID-19 vaccines among german healthcare workers. Biology (Basel). 2021; 10 (8): 752. doi: 10.3390/biology10080752.

46. Pormohammad A., Zarei M., Ghorbani S., Mohammadi M., Razizadeh M. H., Turner D. L., Turner R. J. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021; 9 (5): 467. doi: 10.3390/vaccines9050467.

47. Насонов Е. Л. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021; 59 (1): 5–30. doi: 10.47360/1995-4484-2021-5-30.

48. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) — Vaxzevria (pre-viously COVID-19 Vaccine AstraZeneca) (Other viral vaccines) EPITT no: 19683. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf.

49. Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement, 7 May 2021. https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement-7-may-2021/use-of-the-astrazeneca-covid-19-azd1222-vaccine-updated-jcvi-statement-7-may-2021.

50. MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots.

51. Moreno-Torres V., Gutiérrez Á., Valdenebro M., Ortega A., Cítores M. J., Montero E. Catastrophic antiphospholipid syndrome triggered by mRNA COVID-19 vaccine. Clin Exp Rheumatol. 2022 May; 40 (5): 1054–1055. doi: 10.55563/clinexprheumatol/s3sbgu.

52. Chen Y., Xu Z., Wang P., Li X. M., Shuai Z. W., Ye D. Q., Pan H. F. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022; 165 (4): 386–401. doi: 10.1111/imm.13443.

53. Watanabe T., Minaga K., Hara A., Yoshikawa T., Kamata K., Kudo M. Case report: new-onset rheumatoid arthritis following COVID-19 vaccination. Front Immunol. 2022; 13: 859926. doi: 10.3389/fimmu.2022.859926.

54. Li X., Tong X., Yeung W. W. Y., Kuan P., Yum S. H. H., Chui C. S. L. et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022; 81 (4): 564–568. doi: 10.1136/annrheumdis-2021-221571.

55. Joudeh A. I., Lutf A. Q., Mahdi S., Tran G. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases : a systematic review. Vaccine. 2023; 41 (26): 3801–3812. doi: 10.1016/j.vaccine.2023.05.048

56. Matsuda M., Funakubo Asanuma Y., Emoto K., Sakai S., Okumura N., Yazawa H. et al. New-onset of rheumatic diseases following COVID-19 vaccination : the report of three cases and a literature review. Immunol Med. 2024; 47 (3): 205–216. doi: 10.1080/25785826.2024.2339542.

57. Furer V., Rondaan C., Heijstek M. W., Agmon-Levin N., van Assen S., Bijl M. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.

58. Белов Б. С., Муравьева Н. В. Вакцинопрофилактика инфекций и активность иммуновоспалительных ревматических заболеваний: pro et contra. Антибиотики и химиотер. 2024; 69 (1–2): 65–73. doi: 10.37489/0235-2990-2024-69-1-2-65-73.

59. Bass A. R., Chakravarty E., Akl E. A., Bingham C. O., Calabrese L., Cappelli L. C. et al. 2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023; 75 (3): 449–464. doi: 10.1002/acr.25045.

60. Curtis J. R., Johnson S. R., Anthony D. D., Arasaratnam R. J., Baden L. R., Bass A. R. et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis Rheumatol. 2023; 75 (1): E1–E16. doi: 10.1002/art.42372.

61. Насонов Е. Л., Лила А. М., Мазуров В. И., Белов Б. С., Каратеев А. Е., Дубинина Т. В., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021; 59 (3): 239–254. doi: 10.47360/1995-4484-2021-239-254.

62. Инфекции и ревматические заболевания : руководство для врачей. Под ред. А. М. Лилы, Б. С. Белова. М.: ГЭОТАР-Медиа, 2024; 184. doi: 10.33029/9704-8690-0-IRD-2024-1-184.

63. Фомина Д. С., Салогуб Г. Н., Маслянский А. Л., Гриднева Г. И., Птушкин В. В., Ситникова М. Ю. и др. Безопасность доконтактной профилактики COVID-19 препаратом сипавибарт у лиц, имеющих высокий риск тяжёлого течения коронавирусной инфекции: данные клинического исследования NOVELLA, проведённого в российской популяции. Терапевтический архив. 2024; 96 (12): 1127–1136. doi: 10.26442/00403660.2024.12.203103.

64. Приказ Минздрава Р. Ф. от 12. 12. 2023 N 677н. https://normativ.kontur.ru/document?moduleId=1&documentId=464427&ysclid=m78vm6gkrs457014953.